PAR04-122 Extramural Research Facilities Construction A*

描述(由申请人提供)： 内布拉斯加州大学医学中心的这份提案描述了一项翻新52,900平方英尺的Eppley癌症研究所大楼内部的计划。该大楼于1963年开业，大部分研究都集中在动物身上测试致癌物质和毒素，而该建筑的大部分都用于动物的收容和测试。40年后，这座建筑几乎没有进行过更新和改造，所有系统都处于使用寿命的末期。 然而，埃普利研究所的业务范围和使命已经发生了巨大的变化。该研究所现在是UNMC Eppley癌症中心的学术单位，该中心是一个以母体为基础的大学癌症研究组织，是美国国家癌症研究所指定的61个临床癌症中心之一。埃普利研究所的研究重点已经从动物试验转向癌症的分子和细胞生物学研究，包括开发用于癌症研究的转基因动物模型。 该项目的目的是拆除ECI大楼中陈旧、低效和老化的设施，取而代之的是最先进的实验室、行政和会议空间。ECI大楼内部的这一彻底翻新将提供设施，以保留和支持现有资助研究人员的创新工作；成功招聘并为实现其研究增长目标所需的额外资助研究人员提供实验室；保持其在生物和临床癌症研究方面的领先地位。

DESCRIPTION (provided by applicant): This University of Nebraska Medical Center proposal describes a plan to renovate the entire interior of the 52,900-square-foot Eppley Cancer Institute building. Opened in 1963, most of the research taking place in the building focused on testing carcinogens and toxins on animals, and the majority of the structure was devoted to animal housing and testing. Forty years later, very little updating and remodeling have been done in the building, and all systems are at the end of their service lives. However, the outreach and mission of the Eppley Institute have grown and changed tremendously. The institute is now the academic unit of the UNMC Eppley Cancer Center, a university-wide matrixbased cancer research organization that is one of 61 NCI-designated Clinical Cancer Centers in the country. The Eppley Institute's research focus has changed from animal testing to molecular and cellular biology research in cancer, including development of transgenic animal models for cancer research. The purpose of this project is to remove the antiquat34d, inefficient and deteriorating facilities in the ECI building and replace them with state-of-the-art laboratory, administrative and conference space. This complete renovation of the interior of the ECI building will provide facilities to retain and support the innovative work of current funded investigators; successfully recruit and provide laboratories for the additional funded investigators necessary to reach its research growth objectives; maintain its leadership in biological and clinical cancer research.